Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 2275-2280

  Sharman, Johannah ^a   Pennick, Michael ^a  

^a Shire Pharmaceuticals   (United Kingdom)

Author keywords

Attention deficit hyperactivity disorder; Hydrolysis; LDX; Lisdexamfetamine; Peptidase; Prodrug

Indexed keywords

AMINOPEPTIDASE; AMPHETAMINE; BESTATIN; EDETIC ACID; LISDEXAMFETAMINE; PRODRUG;

ARTICLE; CELL LYSATE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; ERYTHROCYTE; FRACTIONATION; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; MALE; NORMAL HUMAN; PROTEIN BINDING; TREATMENT DURATION;

EID: 84919363618     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S70382     Document Type: Article

References (21)

1. Steer C, Froelich J, Soutullo CA, Johnson M, Shaw M. Lisdexamfetamine dimesylate: a new therapeutic option for attention-defcit hyperactivity disorder. CNS Drugs. 2012;26(8):691–705.
2. Ermer J, Homolka R, Martin P, Buckwalter M, Purkayastha J, Roesch B. Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol. 2010;50(9):1001-1010.
3. Wigal SB, Kollins SH, Childress AC, Squires L; 311 Study Group. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-defcit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3(1):17.
4. Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J; 316 Study Group. Randomized, double-blind, placebo-controlled, crossover study of the effcacy and safety of lisdexamfetamine dimesylate in adults with attention-defcit/hyperactivity disorder: novel fndings using a simulated adult workplace environment design. Behav Brain Funct. 2010;6:34.
5. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6: 317-327.
6. Ermer JC, Haffey MB, Doll WJ, et al. Pharmacokinetics of lisdexamfe-tamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. Drug Metab Dispos. 2012;40(2):290-297.
7. Krishnan S, Moncrief S. An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos. 2007;35(1):180-184.
8. Pennick M. Metabolism of the prodrug lisdexamfetamine dimesylate in human red blood cells from normal and sickle cell disease donors. J Drug Assess. 2013;2:17-20.
9. Powers JC, Asgian JL, Ekici OD, James KE. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev. 2002;102(12): 4639-4750.
10. Rhoads ML, Fetterer RH, Urban JF Jr. Secretion of an aminopeptidase during transition of third- to fourth-stage larvae of Ascaris suum. J Parasitol. 1997;83(5):780-784.
11. Grdisa M, Vitale L. Types and localization of aminopeptidases in different human blood cells. Int J Biochem. 1991;23(3):339-345.
12. Goodman SR, Daescu O, Kakhniashvili DG, Zivanic M. The proteomics and interactomics of human erythrocytes. Exp Biol Med (Maywood). 2013;238(5):509-518.
13. Abramic M, Vitale L. Basic amino acids preferring broad specifcity aminopeptidase from human erythrocytes. Biol Chem Hoppe Seyler. 1992;373(7):375-380.
14. Lochs H, Morse EL, Adibi SA. Uptake and metabolism of dipeptides by human red blood cells. Biochem J. 1990;271(1):133-137.
15. Ellory JC, Swietach P, Gibson JS. Amino acid transport. In: Bernhardt I, Ellory JC, editors. Red Cell Membrane Transport in Health and Disease. Berlin: Springer Verlag; 2003:303–319.
16. Jasinski DR, Krishnan S. Human pharmacology of intravenous lis-dexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009;23(4):410-418.
17. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexam-fetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009;23(4):419-427.
18. Chen L, Teng Y, Xu W. Progress in the development of bestatin analogues as aminopeptidases inhibitors. Curr Med Chem. 2011; 18(7):964-976.
19. Jia MR, Wei T, Xu WF. The analgesic activity of bestatin as a potent APN inhibitor. Front Neurosci. 2010;4:50.
20. Hitzerd SM, Verbrugge SE, Ossenkoppele G, Jansen G, Peters GJ. Positioning of aminopeptidase inhibitors in next generation cancer therapy. Amino Acids. 2014;46(4):793-808.
21. Scornik OA, Botbol V. Cellular uptake of 3H-bestatin in tissues of mice after its intravenous injection. Drug Metab Dispos. 1997;25(7): 798-804.